Best of ASCO - 2014 Annual Meeting

 

Welcome

Ovarian Cancer

Gynecologic Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
BRCA1/BRCA2 mutations behavior and clinical evaluation in Mexican ovarian cancer patients.

Dolores Gallardo-Rincon

e17559

53BP1 as a predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Rachel M Hurley

5538

A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.

Alexandra Leary

5542

A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.

Joshua Millstein

5583

A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trial—A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin.

Jose Alejandro Perez-Fidalgo

TPS5610

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).

Joyce F. Liu

5519

A phase I dose-escalation of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin for the frontline treatment of advanced ovarian cancer.

Leslie M. Randall

5554

A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.

Roisin Eilish O'Cearbhaill

5553

A phase Ib trial of pembrolizumab (Pembro) following adoptive cell therapy (ACT) in patients with platinum-resistant ovarian cancer; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) trial.

Josee-Lyne Ethier

TPS5611

A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.

Robert L. Coleman

5501

AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.

Ignace Vergote

5518

An open-label phase 1 trial of the safety and efficacy of daily subcutaneous SPL-108 injections when used in combination with paclitaxel in patients with platinum-resistant, CD44+, advanced ovarian epithelial cancer.

Eugenia Girda

TPS5608

Apatinib, a novel VEGFR inhibitor, combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer: A single-arm, open-label, phase 2 study.

Chunyan Lan

5515

Assessing delay and barriers to risk-reducing surgery in women with BRCA mutations.

Anne Olsen

5564

Association of diabetes mellitus with an increased risk of recurrence and disease progression in women with ovarian granulosa cell tumors.

Joan Tymon-Rosario

e17521

Association of high tumor mutation (TMB) with DNA damage repair (DDR) alterations and better prognosis in ovarian cancer.

Wenjuan Tian

5512

Association of unplanned hospitalizations after chemotherapy with disease specific survival in a racially ethnically diverse population of women with epithelial ovarian cancer.

Shayan M Dioun

e17517

ATALANTE (ENGOT-ov29): A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.

Jean Emmanuel Kurtz

TPS5607

Bioanalysis of samples from advanced ovarian cancer subjects treated with a combination of DPX-Survivac, metronomic cyclophosphamide, and epacadostat: Preliminary data from the phase Ib DeCidE1 Trial.

Olga Hrytsenko

e17550

Can serum IL-6 be a sentinel biomarker of cancer cachexia in gynecologic cancer patients?

Tomoyuki Yoshikwa

e17544

Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.

Michael Friedlander

5556

Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.

Sandro Pignata

5506

Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease.

Michael-John Devlin

5581

Clinical data from the DeCidE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer.

Oliver Dorigo

5510

Clinical impact of BRCA1 and BRCA2 mRNA expression in ovarian cancer.

Irina Tsibulak

e17533

Clinical relevance of Vav3.1 expression in ovarian cancer and involvement in mechanisms causing genuine multi-drug resistance.

Daniel Uwe Reimer

e17528

Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Richard T. Penson

TPS5609

Combination of triapine, olaparib, and cediranib for epithelial ovarian cancer therapy.

Z Ping Lin

e17551

Combinatorial inhibition of Polo-like kinase 1 (PLK1) and microtubule dynamics to induce synthetic lethality in ovarian cancer cells with CCNE1-amplification.

Sven Becker

e17537

Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.

Tharani Sivakumaran

5568

Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602.

Takashi ONDA

5500

Comprehensive analysis of genomic alterations in Chinese high-grade serous ovarian carcinoma patients.

Fangfang Zhong

e17535

Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.

Megan Buechel

5507

Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.

Juliet Elizabeth Wolford

5508

Cost-effectiveness of niraparib versus routine surveillance, olaparib, and rucaparib for the maintenance treatment of adult patients with ovarian cancer in the United States.

Mark Fisher

5559

CUDC-907, a dual HDAC and PI3K inhibitor, to inhibit cancer progression both in high and low grade ovarian carcinoma cell lines.

Marufa Rumman

e17556

Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial.

Lukas Rob

5509

Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.

David Cibula

e17515

Determinants of severe chronic fatigue among epithelial ovarian cancer survivors: A GINECO VIVROVAIRE study.

Florence Joly

5573

Differences in survival between Caucasians and Asians.

John K. Chan

5570

EDMONd: A feasibility study of elemental diet as an alternative to parenteral nutrition for ovarian cancer patients with inoperable malignant bowel obstruction.

Agnieszka Michael

TPS5605

Effect of adjuvant therapy for stage II and III ovarian cancer in patients older than 70 years.

Samip R. Master

e17557

Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts.

Robert Armbrust

5546

Efficacy and immune modulation of the tumor microenvironment with the combination of the PARP inhibitor rucaparib and CD122-biased agonist NKTR-214.

Andrew Simmons

5582

Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.

Carol Aghajanian

5537

Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.

Ana Oaknin

5545

Exploring ovarian cancer detection using an interdisciplinary investigation of its volatile odor signature.

Lorenzo Ramirez

e17524

Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: Uptake of genetic assessment and testing and impact on patient-reported stress, anxiety and depression.

Sarah S. Lee

5552

Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.

Robert Allen Burger

5517

First results of a prospective national controlled study: Prophylactic Radical Fimbriectomy (NCT01608074), in women with a hereditary familial risk of breast/ovarian cancer—Tolerance and pathological findings.

Eric Leblanc

5574

Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC).

Elena Ioana Braicu

5569

Genomic mutation profiles of paired ovarian cancers (OC) across time.

Julia Fehniger

5521

Histone deacetylase inhibition alters tumor phenotype and stimulates a productive anti-tumor immune response in preclinical models of ovarian cancer.

Tyler McCaw

5585

Identification of outcome-correlated serum cytokine and chemokine clusters in ovarian clear cell carcinoma.

Akira Yabuno

5544

Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.

Jacob Korach

5548

Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced ovarian cancer.

Julia Salinaro

e17531

Incidence of venous thromboembolism in the gynecologic cancer patient population at a single institution after implementation of pre-operative venous thromboembolism prophylaxis.

Elizabeth Hopp

e17529

Inhibition of the Wnt/β-catenin pathway to promote T-cell immunity and survival in a syngeneic mouse model of ovarian cancer.

David W Doo

5566

INNOVATE-3: Phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer.

Eilon David Kirson

TPS5614

Integrated molecular analysis of Asian ovarian cancer: Gene expression and whole exome sequencing analyses from the iPocc Translational Research study (TriPocc).

Ruby Huang

5562

Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.

Michelle K. Wilson

5555

Interval between last neoadjuvant chemotherapy and surgery and between surgery and first adjuvant chemotherapy in ovarian cancer patients.

Alexandre Andre B. A. Da Costa

e17558

LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women—Prospective substudy of the randomized multicenter LION study.

Annette Hasenburg

5575

Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.

Kirsten Timms

5563

Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.

Karina Dahl Steffensen

5540

METRO-BIBF: Phase II, randomised, placebo controlled, multicentre, trial of low dose (metronomic) cyclophosphamide (MCy) with or without nintedanib in relapsed ovarian cancer (ROC).

Marcia Hall

5551

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.

David M. O'Malley

5549

Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.

Min Wang

e17543

Nanoparticle micellar formulation of paclitaxel in combination with carboplatin for women with recurrent platinum sensitive ovarian cancer (OAS07-OVA): Overall survival results of a phase 3 randomized trial.

Nina Heldring

5560

Novel orally bioavailable tubulin inhibitor VERU-111 to suppress ovarian tumor growth and metastasis.

Guannan Zhao

e17538

Olaparib in German routine clinical practice: Updated interim results of the non-interventional study C-PATROL.

Frederik Marme

e17549

Olaparib-induced severe folate deficiency in women with relapsed ovarian cancer: First report and case series.

Jamile M. Shammo

e17540

Outcome of patients undergoing delayed debulking surgery (DDS) in advanced ovarian cancer (OC).

Shanthini M Crusz

e17530

OVARIO: The phase 2, single-arm, open-label study of maintenance therapy with niraparib + bevacizumab in patients with advanced ovarian cancer following response on frontline platinum-based chemotherapy.

Joanie M. Hope

TPS5606

Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial.

Li Li

e17519

Paired somatic and germline genetic testing for ovarian cancer patients: Observations, benefits and implications for treatment.

Daniel Chen

5579

PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.

Susana N. Banerjee

5524

PD-1 inhibitor treatment of platinum-resistant epithelial ovarian cancer.

Jan Oldenburg

e17555

PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.

Jasgit C. Sachdev

5565

Phase 1b study of oncolytic vaccinia virus GL-ONC1 in recurrent ovarian cancer (ROC).

Robert W. Holloway

5577

Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).

Lainie P. Martin

5580

Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

Iurie Bulat

5571

Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Nicole Concin

5567

Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer.

William Rayford Gwin

TPS5613

Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer: An Asian Gynecologic Oncology Group study.

Chyong-Huey Lai

5584

Phylogenetic characteristics as a potential prognostic factor in serous ovarian cancer.

Qin Zhang

e17523

Platinum based chemotherapy selects for PDGFRα dependent angiogenesis.

Nuala McCabe

5578

Potential impact of dietary intervention/counseling on survival in ovarian cancer patients: Results from an observational study.

Jessica Michalak

5541

Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial.

Florian Heitz

5550

Predictive factors for prolonged response to olaparib as maintenance therapy in ovarian cancer patients with BRCA mutations.

Sana Intidhar Labidi-Galy

5558

PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.

Charlie Gourley

TPS5612

Prognostic relevance of supradiaphragmatic lymph nodes in advanced stage ovarian cancer.

Daniel Uwe Reimer

e17534

Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.

Xavier Paoletti

5576

QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.

Kathleen N. Moore

5514

Real-world Effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA) : A Korean Gynecologic Oncology Group study (KGOG 3041).

Jung-Yun Lee

e17547

Role of primary surgery for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer.

Philipp Harter

5543

Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab.

Stefan Kommoss

5520

Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).

Anna Fagotti

5516

Survival and safety in patients with advanced ovarian cancer undergoing aggressive primary and interval debulking surgery.

Shinichi Tate

e17525

Survival impact of secondary cytoreductive surgery for platinum-sensitive relapsed serous ovarian cancer.

Jingjing Liu

e17546

The clinical outcome of FAP+ cancer-associated fibroblasts in high-grade serous ovarian cancer.

Hanna Dahlstrand

e17526

The impact of health related quality of life (HRQoL) on short term survival of recurrent ovarian cancer patients: Analysis of pooled data from the North-Eastern German Society of Gynecological Oncology (NOGGO) meta data base.

Jalid Sehouli

5539

TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

Panagiotis A. Konstantinopoulos

106

Topotecan (T) + Pazopanib (P) in platinum-resistant or intermediate-sensitive ovarian cancer: a phase I/II single-arm multicentre trial of the North-Eastern German Society of Gynaecologic Oncology: TOPAZ.

Radoslav Chekerov

e17553

Toxicity profile of patients with gynecological cancers (Gyne) enrolled in phase I trials.

Yeh Chen Lee

5572

Treating recurrent tuboovarian carcinoma with multiple lines of bevacizumab-based therapy: Feasibility and effectiveness in the clinical routine.

Christian M. Kurbacher

e17541

Treatment pattern differences across the United States and EU5 among patients with ovarian cancer.

Chitra Karki

e17516

Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.

Johanne I Weberpals

5561

Tumor regression grading after neoadjuvant chemotherapy predicts long-term outcome of stage IIIC epithelial ovarian cancer.

Mingyi Zhou

5547

Using GeneReader NGS system to identify mutations in BRCA 1/2 genes in matched FFPE and blood samples.

Vishal Kapoor

e17536

Utility of PETCT over conventional imaging in ovarian cancer.

Sarah Cook

e17522